503A and 503B refer to sections of federal law that establish different conditions for drug compounding. They describe regulatory frameworks, not grades of effectiveness.

Compounded drugs under either framework are not FDA-approved. FDA does not review the finished preparations for safety, effectiveness or quality before they are marketed.[1]

503A: generally patient-specific compounding

Section 503A applies to compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, when the relevant legal conditions are met. The framework generally involves an individual patient's prescription.[1][4]

State boards of pharmacy ordinarily have primary responsibility for day-to-day oversight of state-licensed pharmacies that are not registered as outsourcing facilities. FDA also conducts surveillance and for-cause inspections of these pharmacies.[1]

Drugs compounded in accordance with 503A conditions are exempt from certain federal requirements, including current good manufacturing practice requirements. Other requirements still apply, including the prohibition on preparing drugs under insanitary conditions.[1]

503B: registered outsourcing facilities

An outsourcing facility elects to register with FDA under section 503B and must meet that section's conditions. Its compounded drugs remain subject to current good manufacturing practice requirements.[2]

These facilities are inspected by FDA on a risk-based schedule. They must also meet reporting requirements, including reporting adverse events and information about the products they compound.[2]

Registration is a facility status. It does not give every medication made there FDA approval.

How this helps with an actual prescription

Knowing the framework helps identify which oversight and manufacturing requirements apply. It does not settle whether a particular medication is appropriate, whether a claimed benefit is supported or whether a specific product has a quality problem.

FDA has documented serious problems with compounded drugs, including contamination and incorrect amounts of active ingredient. The relevant question is how the particular preparation is sourced, made, labeled and followed up, alongside the medical reason for prescribing it.[1][3]

For a proposed order, verify the facility’s identity and the specific preparation. An “FDA registered” claim describes the facility; it does not mean the compounded medication is FDA-approved.